Assessing a peptide’s development prospects early is mostly a matter of identifying which liabilities are intrinsic to the sequence and which are engineering problems.
Key Takeaways
- Susceptibility to proteolysis and to chemical degradation determines whether a sequence is tractable at all.
- Length, hydrophobic content, and cysteine count all influence synthesis difficulty and cost.
- Evaluate stability, then manufacturability, then potency, then delivery.
Stability as the first filter
Susceptibility to proteolysis and to chemical degradation determines whether a sequence is tractable at all. Liability motifs such as Asn-Gly or exposed methionine can be engineered out, but pervasive instability usually is not worth pursuing.
Potency relative to achievable exposure
A peptide must be active at concentrations reachable in the target compartment. Weak potency combined with rapid clearance is a combination that formulation work rarely rescues, and it should be recognised early.
For related mechanism work, see peptide regulatory classification.
Manufacturability
Length, hydrophobic content, and cysteine count all influence synthesis difficulty and cost. A sequence that cannot be produced reproducibly at acceptable purity is not a candidate regardless of its biology.
Immunogenicity and safety
Aggregation propensity and novel sequence content drive immune risk. Both can be mitigated but not eliminated, and both need assessment before significant investment.
A practical screening sequence
Evaluate stability, then manufacturability, then potency, then delivery. Reversing that order wastes effort on molecules whose chemistry will not support development, which is the most common way peptide programmes lose time.
Experimental Conditions and Practical Setup
Early assessment runs a short stability panel alongside a synthesis feasibility review, because both are cheap and either can end a programme. Only sequences that pass both are taken into potency optimisation, since optimising a molecule that cannot be made reproducibly or that degrades in buffer wastes the most expensive stage of work.
Screening order and why it matters
| Order | Attribute | Reason for the position |
|---|---|---|
| 1 | Chemical and enzymatic stability | Intrinsic; rarely fixable later |
| 2 | Manufacturability | Determines cost and feasibility |
| 3 | Potency relative to exposure | Guides whether delivery is realistic |
| 4 | Immunogenicity risk | Mitigable but must be monitored |
Practical Notes for the Bench
- Screen stability and manufacturability before optimising potency.
- Treat liability motifs as engineering targets, not as project-ending defects.
- Assess achievable exposure alongside potency.
Frequently Asked Questions
Which property matters most?
Stability, because an unstable sequence undermines every other attribute and is often sequence-intrinsic.
Can formulation rescue a weak candidate?
Rarely. Formulation improves stability and delivery but cannot overcome inadequate potency relative to achievable exposure.
When should manufacturability be assessed?
Early, alongside biology, since a sequence that cannot be made reproducibly is not a candidate at all.
Can formulation rescue a weak candidate?
Rarely. Formulation addresses stability and delivery but cannot overcome inadequate potency relative to the exposure that is actually achievable.
Related Reading
- peptide regulatory classification
- peptide stapling technology
- antimicrobial peptide therapeutics
- peptide synthesis scale-up
- peptide lyophilisation
References & Further Reading
- Erasmus MF et al. Developing drug-like single-domain antibodies (VHH) from in vitro libraries. MAbs. 2025. PubMed 40562779
- Zhang Y et al. Evolution of phage display libraries for therapeutic antibody discovery. MAbs. 2023. PubMed 37222232
- Bak A et al. Peptide Developability at the Discovery-to-Development Interface–Current State and Future Opportunities. AAPS J. 2015. PubMed 25823670
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
This article summarises published research practice for laboratory professionals. It is not a guide to human use, and no claim of therapeutic benefit is made or implied.
Reviewed by Dr. Marcus Feld, Molecular Pharmacology, In Vitro Models.